Mainz Biomed NV (NASDAQ:MYNZ) Short Interest Update

Mainz Biomed NV (NASDAQ:MYNZ) saw a significant drop in short interest in December. As of December 31st, there was short interest totaling 173,183 shares, a drop of 18.5% from the December 15th total of 212,454 shares. Based on an average daily trading volume, of 266,464 shares, the days-to-cover ratio is presently 0.6 days. Approximately 1.9% of the shares of the stock are short sold. Approximately 1.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 266,464 shares, the days-to-cover ratio is presently 0.6 days.

Mainz Biomed Trading Down 5.2%

Shares of MYNZ opened at $1.10 on Wednesday. The stock’s fifty day simple moving average is $1.15 and its 200-day simple moving average is $1.47. The firm has a market capitalization of $9.97 million, a PE ratio of -0.02 and a beta of 0.26. Mainz Biomed has a 12-month low of $0.92 and a 12-month high of $8.20. The company has a quick ratio of 0.43, a current ratio of 0.52 and a debt-to-equity ratio of 0.44.

Mainz Biomed (NASDAQ:MYNZ) last announced its quarterly earnings data on Friday, September 26th. The company reported ($1.32) EPS for the quarter. The company had revenue of $0.14 million during the quarter. As a group, research analysts predict that Mainz Biomed will post -23.6 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on MYNZ shares. Wall Street Zen upgraded shares of Mainz Biomed to a “hold” rating in a research report on Saturday, December 27th. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Mainz Biomed in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Mainz Biomed presently has a consensus rating of “Hold” and a consensus target price of $14.00.

Hedge Funds Weigh In On Mainz Biomed

A hedge fund recently raised its stake in Mainz Biomed stock. Armistice Capital LLC raised its holdings in Mainz Biomed NV (NASDAQ:MYNZ) by 45.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 285,000 shares of the company’s stock after acquiring an additional 88,400 shares during the quarter. Armistice Capital LLC owned about 6.23% of Mainz Biomed worth $402,000 as of its most recent SEC filing.

About Mainz Biomed

Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.

The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer.